CSIMarket


Ptc Therapeutics inc   (PTCT)
Other Ticker:  
 


 

Ptc Therapeutics inc

PTCT's Financial Statements and Analysis



Ptc Therapeutics inc narrowed forth quarter of 2023 net loss per share of $-1.97 compare to net loss per share of $-2.32 recorded in the same quarter a year ago a decrease compare to $-1.76 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -1.97 $  307 Mill
$+0.35     $+140M     +83.41 %



Ptc Therapeutics Inc 's Revenue rose by 83.41 % in forth quarter of 2023 (Dec 31 2023) year on year, to $307 million and advanced by 56.2 % sequentially.


Ptc Therapeutics Inc is

More on PTCT's Income Statement



Ptc Therapeutics Inc 's in theforth quarter of 2023 recorded net loss of $-155.792 million, an improvement compare to net loss of $-170.889 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on PTCT's Growth

Ptc Therapeutics Inc Inventories
Inventories grew by 40.21 % to $31 million from IV. Quarter a year ago, sequentially inventories fell by -14.47 %. PTCT's Cash flow In the forth quarter of 2023 company's net cash flow was $429 million, capital expenditures fell by -26.9975.43%, to $-28 millions compare to same quarter a year ago

More on PTCT's Cash flow Statement


Ptc Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Ptc Therapeutics inc payed $ -2.12 cash per share, on a free-cash flow basis .


Tangible Book value fell to $ -17.10 per share from $ -15.61.

Company repurchased 0.51 million shares or 0.68 % in Dec 31 2023.


More on PTCT's Dividends

 Market Capitalization (Millions) 2,093
 Shares Outstanding (Millions) 75
 Total Debt (Millions $) 284
 Revenue (TTM) (Millions $) 938
 Net Income (TTM) (Millions $) -627
 Cash Flow (TTM) (Millions $) 314
 Capital Exp. (TTM) (Millions $) -121
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 700




Ptc Therapeutics inc does not pay out common stock dividend.

In trailing twelve-month period Ptc Therapeutics inc had negative $ -2.12 cash flow per share, on a free-cash flow basis .


Tangible Book value fell to $ -17.10 per share from $ -15.61.

Company repurchased 0.51 million shares or 0.68 % in Dec 31 2023.


More on PTCT's Balance Sheets

 Market Capitalization (Millions) 2,093
 Shares Outstanding (Millions) 75
 Total Debt (Millions $) 284
 Revenue (TTM) (Millions $) 938
 Net Income (TTM) (Millions $) -627
 Cash Flow (TTM) (Millions $) 314
 Capital Exp. (TTM) (Millions $) -121
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 700
   


  News about Ptc Therapeutics inc Earnings

How Ptc Therapeutics Inc is Overcoming Losses with a Remarkable Revenue Surge

Ptc Therapeutics Inc, a leading biopharmaceutical company, recently released its financial results for the October to December 31, 2023 fiscal period. Despite reporting a net loss of $-1.97 per share, the company showed improvement compared to the same period last year when the loss per share was $-2.32. Notably, this also marks an increase from the previous reporting period's loss per share of $-1.76.
On a positive note, Ptc Therapeutics Inc witnessed a significant rise in revenue during this fiscal period, with a strong growth of 83.412%. The company generated $307.06 million in revenue, compared to $167.41 million in the same period a year ago. Additionally, the sequential revenue surged by 56.202% fr...

Ptc Therapeutics Inc. Grapples with Impending Crisis Amidst Decreased Orders in Q3 2023

/>Ptc Therapeutics Inc., a leading biopharmaceutical company, experienced a challenging July to September 2023 period, overwhelmed by lower demand and dwindling revenue. Despite recent gains in share price, the company's financials raise concerns as it reported a larger shortfall and decreased revenue year on year. This article will analyze the financial results to delve deeper into the factors contributing to Ptc Therapeutics Inc.'s struggling performance.
Dwindling Revenue and Extended Deficit:
During the July to September 2023 period, Ptc Therapeutics Inc. faced a significant decline in revenue, marking a year-on-year decrease of 9.465%. Revenue stood at $196.58 million, compared to $213.81 millio...

Ptc Therapeutics Inc Reports Unexpected Jump in Q2 2023 Revenue, Encountering a Paradoxical Slump

Financial news report:

Ptc Therapeutics Inc, a biopharmaceutical company, has reported a significant surge in revenue for the April to June 30, 2023 period. The company's revenue increased by 29.169% to $213.81 million compared to the corresponding reporting period a year prior. However, it also reported an increased deficit per share at $-2.66 per share, compared to $-1.88 per share in the previous year.
Interestingly, despite the increase in revenue, there was a slight decrease in revenue by -2.983% from $220.38 million. Additionally, Ptc Therapeutics Inc recorded a net deficit of $-198.883 million for the most recent fiscal period, which was larger than the $-152.087 million deficit from the...


Date modified: 2024-03-09T22:52:40+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com